Bristol-Myers Squibb

Bristol Myers Squibb to acquire RayzeBio for $4.1 billion in cash

31 Dec 2023

American multinational pharmaceutical company Bristol Myers Squibb on Tuesday said it would buy RayzeBio for about $4.1 billion to bolster its cancer drug business

Bristol Myers Squibb to acquire MyoKardia for $13.1 billion in cash

07 Oct 2020

Bristol-Myers to acquire Celgene in $74-bn cash-and-stock deal

03 Jan 2019

Celgene shareholders will receive one Bristol-Myers Squibb share and $50 in cash for each share held, or $102.43 per share, a premium of 53.7 per cent to Celgene’s Wednesday close, besides one tradable contingent value right for each share held

GlaxoSmithKline’s majority-owned HIV business to buy drugs from US rival Bristol-Myers Squibb

18 Dec 2015

Drugmaker Bristol-Myers Squibb acquires rights to Promedior Inc and its experimental drug PRM-151

01 Sep 2015

Health ministry seeks compulsory licence for Bristol-Myers' cancer drug

03 Apr 2014

A month’s dosage of Bristol-Myers Squibb’s patented drug Dasatinib, which is sold under the brand name `Sprycel’, costs around Rs60,000

Bristol-Myers Squibb enters $482-mn Latin American deal with Reckitt Benckiser

12 Feb 2013

Bristol-Myers Squibb may sell some brands in Mexico, Brazil: report

01 Feb 2013

AstraZeneca to pay Bristol-Myers Squibb $135 mn more for Amylin drug rights

10 Aug 2012

AstraZeneca will pay the $135 million to Bristol-Myers Squibb after the anti-trust and other competition regulators approve the acquisition of Amylin

Bristol-Myers Squibb launches tender offer for Amylin

12 Jul 2012

Bristol-Myers Squibb, AstraZeneca expand alliance through Amylin acquisition

30 Jun 2012

Amylin reportedly rejects Bristol-Myers $3.5-bn bid

30 Mar 2012

Bristol-Myers to acquire hepatitis C oral drug developer Inhibitex for $2.5 bn

09 Jan 2012

Bristol-Myers Squibb over the weekend said that it will buy Inhibitex Inc, for about $2.5 billion in cash in order to expand its broad hepatitis C portfolio

AstraZeneca - Bristol-Myers to present new data on diabetes drug

27 Oct 2011

Bristol-Myers Squibb to acquire Amira Pharma in a $475 million deal

22 Jul 2011

Bristol-Myers Squibb offers 84-% premium to buy ZymoGenetics for $885 million

08 Sep 2010

AstraZeneca, Bristol-Myers Squibb in diabetes research alliance

01 Apr 2010

Bristol-Myers to divest Mead Johnson for $7.69 billion

16 Nov 2009

Leading maker of children's nutritional products, the over 100-year Mead Johnson had 2008 sales of nearly $2.6 billion

Sigma acquires Bristol-Myers Sqibb’s brands

07 Sep 2009

AstraZeneca says its new anti-clotting drug better than Plavix

31 Aug 2009

Bristol-Myers to acquire biotechnology company Medarex for $2.4 billion

23 Jul 2009

US drugmaker Bristol-Myers Squibb said yesterday that it is acquiring biotechnology company Medarex Inc, a for $2.4 billion to expand its oncology and immunology pipeline

Bristol-Myers, Syngene open new R&D facility

24 Mar 2009

Bristol-Myers Squibb files IPO registration for Mead Johnson

16 Sep 2008

ImClone rejects Bristol-Myers Squibb's $4.3 billion bid; cites $6.1 billion fresh offer

10 Sep 2008

Biotech company ImClone Systems has rejected Bristol-Myers Squibb's $4.3 billion bid as too low, saying it has received a higher offer from a large pharmaceutical company.

Carl Icahn finds Bristol-Myers' offer for ImClone Systems low

04 Aug 2008